Yep, agree. This has tremendous potential. If I had to bet on a single ASX speccy to ten bag within 18 months, I'd choose NYR, based purely on cholesterol.
"A key advantage of the Phase I study is not only will it measure the safety and tolerability of Nyrada’s drug candidate, but it will also evaluate its efficacy"
